Key Points
- Major shareholder Ah Equity Partners Bio II, L.L. sold 5,000,000 Nautilus Biotechnology shares on June 2 at an average price of $2.35, totaling $11.75 million. After the sale, it still held 971,885 shares, an 83.73% reduction in its stake.
- Nautilus Biotechnology stock opened at $2.68 and has a market cap of about $340.6 million. The shares have traded between $0.62 and $4.31 over the past year.
- The company recently reported a quarterly loss of $0.12 per share, which was better than the expected loss of $0.14. Analysts currently have a Hold consensus rating, with an average target price of $4.00.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm's stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the transaction, the insider directly owned 971,885 shares in the company, valued at $2,283,929.75. This represents a 83.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Nautilus Biotechnology Stock Performance
Shares of Nautilus Biotechnology stock opened at $2.68 on Friday. The firm has a market capitalization of $340.57 million, a price-to-earnings ratio of -5.83 and a beta of 0.75. Nautilus Biotechnology, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $4.31. The stock has a 50 day moving average of $2.90 and a 200 day moving average of $2.46.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its earnings results on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on NAUT. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nautilus Biotechnology in a research note on Tuesday, April 21st. Guggenheim upped their target price on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a "buy" rating in a research report on Friday, February 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $4.00.
Check Out Our Latest Report on NAUT
Hedge Funds Weigh In On Nautilus Biotechnology
Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its stake in Nautilus Biotechnology by 5.4% during the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company's stock worth $1,989,000 after purchasing an additional 52,448 shares during the period. Sentinel Trust Co. LBA purchased a new position in Nautilus Biotechnology during the fourth quarter worth approximately $1,462,000. Geode Capital Management LLC raised its stake in Nautilus Biotechnology by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company's stock worth $1,094,000 after purchasing an additional 7,307 shares during the period. Corient Private Wealth LLC raised its stake in Nautilus Biotechnology by 860.0% during the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company's stock worth $316,000 after purchasing an additional 390,000 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Nautilus Biotechnology by 15.3% during the first quarter. Dimensional Fund Advisors LP now owns 329,123 shares of the company's stock worth $1,274,000 after purchasing an additional 43,684 shares during the period. Hedge funds and other institutional investors own 50.71% of the company's stock.
Nautilus Biotechnology Company Profile
(
Get Free Report)
Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.
Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
